Cardiovascular diseases (CVDs) have become a global public health
challenge, with over 500 million patients worldwide suffering from conditions
like myocardial infarction, pulmonary embolism, and cerebral thrombosis. As a
first-line thrombolytic agent, urokinase plays a crucial role in dissolving
blood clots and restoring blood circulation, making its stable supply and high
quality vital for clinical treatment. In this booming market, choosing a
reliable Urokinase manufacturer is the key to ensuring therapeutic efficacy,
regulatory compliance, and long-term cooperation benefits.
Kangyuan, a leading pharmaceutical enterprise with years of experience in
biotech research and production, stands out as a trusted Urokinase manufacturer.
Adhering to the concept of "quality first, compliance foremost", Kangyuan has
built a comprehensive production and quality control system that meets
international standards. Unlike traditional extraction methods with potential
safety risks, Kangyuan adopts advanced recombinant DNA technology to produce
urokinase, which significantly improves product purity, stability, and safety
while resolving ethical concerns related to traditional urine-sourcing
processes.
All production processes of Kangyuan’s urokinase strictly comply with WHO
GMP and PIC/S guidelines. From raw material screening to finished product
testing, each batch undergoes multi-stage quality inspections, including viral
clearance testing, activity assay, and purity analysis, to ensure zero
contamination and consistent product performance. With a professional R&D
team, Kangyuan continuously optimizes production technology, launching
low-molecular-weight urokinase products that reduce bleeding risks and improve
patient compliance, catering to the evolving clinical needs of global healthcare
institutions.
Backed by strong production capacity and global logistics networks,
Kangyuan has established stable cooperation with partners in Southeast Asia,
Europe, and other regions, leveraging the "Belt and Road" initiative to expand
its international market share. The global urokinase market is projected to
reach USD 673 million by 2031, with a steady CAGR of 5.2%, driven by the aging
population and rising CVD incidence. As a reliable Urokinase manufacturer,
Kangyuan is well-positioned to help partners seize market opportunities with
high-quality products, competitive pricing, and comprehensive after-sales
support.
Whether you are a pharmaceutical distributor, hospital procurement
department, or research institution, Kangyuan provides customized cooperation
solutions to meet your specific needs. For inquiries about our urokinase
products, production capacity, or cooperation opportunities, please contact us
directly. Let’s work together to advance global thrombolytic therapy and create
greater value for public health.